Fu YX - Search Results

1

A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains.

Zhang Z, He Q, Zhao W, Li Y, Yang J, Hu Z, Chen X, Peng H, Fu YX, Chen L, Lu L. Zhang Z, et al. Among authors: fu yx. J Clin Med. 2022 Jul 18;11(14):4164. doi: 10.3390/jcm11144164. J Clin Med. 2022. PMID: 35887928 Free PMC article.

2

A mouse model for HBV immunotolerance and immunotherapy.

Yang D, Liu L, Zhu D, Peng H, Su L, Fu YX, Zhang L. Yang D, et al. Among authors: fu yx. Cell Mol Immunol. 2014 Jan;11(1):71-8. doi: 10.1038/cmi.2013.43. Epub 2013 Sep 30. Cell Mol Immunol. 2014. PMID: 24076617 Free PMC article.

3

Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication.

Liang Y, Yang K, Guo J, Wroblewska J, Fu YX, Peng H. Liang Y, et al. Among authors: fu yx. Sci Rep. 2015 May 20;5:10406. doi: 10.1038/srep10406. Sci Rep. 2015. PMID: 25993659 Free PMC article.

4

CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.

Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM. Liu X, et al. Among authors: fu yx. Nat Med. 2015 Oct;21(10):1209-15. doi: 10.1038/nm.3931. Epub 2015 Aug 31. Nat Med. 2015. PMID: 26322579 Free PMC article.

5

Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.

Zhu D, Liu L, Yang D, Fu S, Bian Y, Sun Z, He J, Su L, Zhang L, Peng H, Fu YX. Zhu D, et al. Among authors: fu s, fu yx. J Immunol. 2016 Apr 1;196(7):3079-87. doi: 10.4049/jimmunol.1502061. Epub 2016 Mar 2. J Immunol. 2016. PMID: 26936879 Free PMC article.

6

PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment.

Ren Z, Peng H, Fu YX. Ren Z, et al. Among authors: fu yx. Cancer Discov. 2016 May;6(5):477-8. doi: 10.1158/2159-8290.CD-16-0307. Cancer Discov. 2016. PMID: 27138562 Free PMC article.

7

CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.

Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, Liu X, Liang Y, Peng H, Fu YX. Ren Z, et al. Among authors: fu yx. Clin Cancer Res. 2017 Jan 1;23(1):193-203. doi: 10.1158/1078-0432.CCR-16-0040. Epub 2016 Jun 27. Clin Cancer Res. 2017. PMID: 27354469 Free PMC article.

8

Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.

Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y, Fu S, Guo J, Liu L, Su L, Wang FS, Fu YX, Peng H. Bian Y, et al. Among authors: fu s, fu yx. Hepatology. 2017 Oct;66(4):1067-1082. doi: 10.1002/hep.29239. Epub 2017 Aug 26. Hepatology. 2017. PMID: 28445927 Free PMC article. Clinical Trial.

9

Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.

Liao J, Luan Y, Ren Z, Liu X, Xue D, Xu H, Sun Z, Yang K, Peng H, Fu YX. Liao J, et al. Among authors: fu yx. Cancer Immunol Res. 2017 Jul;5(7):560-570. doi: 10.1158/2326-6066.CIR-16-0221. Epub 2017 May 22. Cancer Immunol Res. 2017. PMID: 28533311 Free PMC article.

10

PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.

Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX. Tang H, et al. Among authors: fu yx. J Clin Invest. 2018 Feb 1;128(2):580-588. doi: 10.1172/JCI96061. Epub 2018 Jan 16. J Clin Invest. 2018. PMID: 29337303 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

595 results

Search Page

Filters